Clorox Co (CLX) Stock Price Today
Aura AI Summary
Key Stats
- $11.65BMarket Cap
- -Volume
- Consumer StaplesSector
- $131.4352W High
- $86.1252W Low
- -Typical Hold Time
- $14.95BEnterprise Value
- 5.15%Div Yield
- -Trading Activity
Track Clorox Co (CLX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Clorox Co has traded between a low of $86.12 and a high of $131.43, highlighting its annual price range. Buy and sell Clorox Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Most Recent News
US chip stocks fall on fears over new Chinese Kimi K3 model, despite strong earnings from TSMC and ASML.
US semiconductor stocks dropped sharply after the introduction of a new Chinese chip model called Kimi K3, which rattled investors despite strong earnings and raised guidance from major players like TSMC and ASML. The SOXX ETF fell 1.5%, reflecting b...
S&P 500 falls 1.6% as investors shift from growth to value amid inflation and geopolitical concerns
Last week, the S&P 500 dropped 1.6% as investors moved away from large-cap growth stocks toward value and defensive sectors. Energy and commodities outperformed, while technology and momentum stocks lagged due to renewed geopolitical tensions and inf...
Medicus Pharma's redesigned Teverelix study gets FDA and IRB approval, cutting costs and patient numbers significantly.
Medicus Pharma announced that its redesigned clinical study protocol for Teverelix, a next-generation hormone antagonist for men's health, has received approval from the Institutional Review Board and conditional acceptance from the FDA. The revised ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.